XML 69 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended 24 Months Ended
Oct. 31, 2017
Mar. 31, 2018
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Collaboration and Other Agreements [Line Items]            
Revenues     $ 77,447 $ 104,883 $ 64,188  
Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Non-refundable upfront payment   $ 150,000        
Amounts recognized     70,000      
Transaction price $ 154,000          
Clinical trial activities selling price amount           $ 4,000
Minimum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Potential proceeds from royalties percent 15.00%          
Maximum | Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Potential development and regulatory milestone payments $ 420,000          
Potential commercial milestone payments $ 330,000          
Potential proceeds from royalties percent 24.00%          
Revenues From License Agreements | Incyte MGA012 Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Revenues $ 150,000   15,000 40,000 100  
Revenues From License Agreements | Incyte MGA012 Clinical Services | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Revenues     7,800 1,400    
Revenues From License Agreements | Incyte MGA012 Supply Agreement | Incyte Corporation (Incyte)            
Collaboration and Other Agreements [Line Items]            
Revenues     $ 1,500 $ 8,600 $ 22,100